JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI,Aug. 27,2024--JW Therapeutics (HKEx: 2126),an independent and innovative biotechnology company focusing on developing,manufacturing and commercializing cell immunotherapy products,announced t










